Kinnate Biopharma Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nima Farzan
- Full Time Employees
- 84
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 103 Montgomery Street San Francisco CA United States of America 94129
- IPO Date
- Dec 3, 2020
- CIK
- 0001797768
- Website
- kinnate.com
- Similar Companies
- Business
- Kinnate Biopharma Inc. Kinnate Biopharma Inc. (Nasdaq: KNTE), founded in 2018 and headquartered in San Diego, California, with additional operations in San Francisco, California, operates as a clinical-stage precision oncology company that discovers, designs, and develops small molecule kinase inhibitors targeting validated oncogenic drivers of cancer for which approved therapies are limited or ineffective. The company focuses on patient populations with genetically driven solid tumors lacking targeted treatments, those exhibiting intrinsic resistance to existing therapies, or those developing acquired resistance; its proprietary pipeline leverages structure-based drug design emphasizing high selectivity, optimized pharmaceutical properties, broad genetic alteration coverage, and brain penetration capabilities. Core product candidates include the investigational pan-RAF inhibitor exarafenib for BRAF- and NRAS-driven advanced adult solid tumors such as melanoma and non-small cell lung cancer; the investigational FGFR inhibitor KIN-3248 targeting FGFR2/3 alterations in cancers including cholangiocarcinoma; a brain-penetrant MEK inhibitor KIN-7136 designed for combination with exarafenib in RAF inhibitor-pretreated patients; a highly selective c-MET inhibitor KIN-8741 addressing overexpression and resistance mutations in non-small cell lung cancer and other solid tumors; and an early-stage brain-penetrant CDK4-selective program. In recent major developments, Kinnate sold global rights to exarafenib and related pan-RAF assets to Pierre Fabre Laboratories in March 2024 pursuant to an asset purchase agreement amid its strategic review. XOMA Royalty Corporation XOMA Royalty Corporation acquired Kinnate in April 2024 through a tender offer and merger, adding approximately $9.5 million in net cash to its balance sheet while gaining control of the remaining pipeline programs. In April 2025, XOMA Royalty sold all five acquired Kinnate pipeline assets—encompassing the FGFR, MEK, c-MET, and CDK4 programs—for upfront and milestone payments up to $270 million plus low single- to mid-teen royalties on future commercial sales, with 85% of pre-2029 proceeds allocated to legacy Kinnate shareholders via contingent value rights. These transactions followed a 2023 strategic restructuring involving 70% workforce layoffs and discontinuation of three programs, alongside addition of the MEK and c-MET candidates earlier that year. Kinnate primarily serves global oncology markets, concentrating on precision medicine for advanced solid tumors.
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: What Does It Mean for the Stock?
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA
KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
7 Stocks With Promising Upside Potential for 100% Returns
4 Penny Stocks To Buy According To Insiders This Quarter
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: Here's What You Should Know
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022